Navigation Links
Frost & Sullivan New Product Innovation Award Presented to Brainsway for Its Deep Transcranial Magnetic Stimulation (dTMS) Device
Date:2/28/2012

LONDON, Feb. 28, 2012 /PRNewswire/ -- Based on its recent analysis of the neuro-psychiatric devices market, Frost & Sullivan recognises Brainsway with the 2012 Global Frost & Sullivan New Product Innovation Award. Brainsway's cutting-edge deep Transcranial Magnetic Stimulation (dTMS) is the only non-invasive technique that can be used for the treatment of depression and other neuro-psychiatric disorders without causing any significant side effects.

"The system has shown high efficacy compared to conventional treatment methods for depression and also the standard TMS systems that are currently used in the market," notes Frost & Sullivan Research Analyst Brahadeesh Chandrasekaran. "Opinion leaders across Europe and the United States are already using this device and the clinical evidence so far suggests that Brainsway's dTMS is highly efficient and extremely promising for the treatment of neuro-psychiatric disorders."

There are a few other TMS devices in the market that can activate brain surface cells. Brainsway's deep TMS, however, is the only device that can activate brain cells in deeper regions.

"The device has obtained the CE mark for treating depression, bipolar disorder, schizophrenia, post-traumatic stress disorder (PTSD) and Parkinson's disease," says Chandrasekaran. "It is on the last stretch of a multi-centre trial for obtaining FDA approval for treating depression and has received an IDE for starting another multi-centre trial in bipolar disorder patients."

In conventional treatment methods (both drug therapy and electro-convulsive therapy), patients are prone to high risk of side effects. In comparison, Brainsway's dTMS system is the only TMS system that allows direct, non-invasive activation of deep brain cells.

Its unique magnetic coil design produces the magnetic pulses required to activate the deeper brain structures without causing any side effects, eliminating the need for anaesthesia and hospitalisation.

Potential clinical applications in more than 10 to 15 different types of neuro-psychiatric disorders, coupled with the benefits offered to both patients and medical professionals, are set to ensure the widespread acceptance of Brainsway's dTMS.

Frost & Sullivan presents this award to the company that has demonstrated excellence in developing a product with innovative elements that leverages leading edge technologies, that offers valued added features and benefits, supports increased customer ROI and has the potential for enhanced customer acquisition/penetration.

Frost & Sullivan Best Practices awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Brainsway Ltd.

Brainsway Ltd. is dedicated to the development and marketing of Deep TMS (Transcranial Magnetic Stimluation) systems - novel, noninvasive medical devices for treatment of a wide range of neurological and psychopathological disorders. In principle, any brain-related disorder that is associated with pathological activity of specific brain sites may be treated by this method. Potential applications include addiction, schizophrenia, obesity, eating disorders, Parkinson's disease, Alzheimer's disease, autism and post-traumatic stress disorder.

Our initial focus is the treatment of major depression. The unique technology of Brainsway is based on patents filed by the U.S. National Institute of Health (NIH) and by the company. Brainsway has an exclusive license from the NIH for the patent and technology. Headquartered in Jerusalem, Israel, the company's ordinary shares and warrants trade on the Tel Aviv Stock Exchange under the symbol 'BRIN'.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

Contact:
Catherine Brassell
Best Practices
Frost & Sullivan
catherine.brassell@frost.com
P: +27(0)21 680 3267
www.frost.com

 


'/>"/>
SOURCE Frost & Sullivan
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan Lauds Siemens Healthcares Unique, Multipurpose Gamma Camera that Sets it Apart from the Competition in the Nuclear Cardiology Market
2. A Secret to Ward Off Jack Frosts Drying Effect on Your Skin: The AmLactin® Family of Moisturizers
3. Frost and Sullivan Recognizes AT&Ts Innovative mHealth Strategy
4. Frost & Sullivan Honors Acuo Technologies with Product Leadership Award in Medical Imaging Informatics
5. KJAYA Medical Honored with 2011 Frost & Sullivan Award for Technology Innovation in Web-based Medical Imaging Data Management
6. Frost & Sullivan Speaks Candidly with U.S. Pharmacists
7. Frost & Sullivan Honors ZONARE for Ultrasound Innovation
8. Awarepoint Corporation Receives Frost & Sullivans 2011 North American RFID and RTLS Healthcare Competitive Strategy Leadership Award
9. China Medicine Corporation Dismisses Frazer Frost as Auditor
10. Frost & Sullivan Recognizes EDDA Technology for its Pioneering Role in Medical Imaging Analytics
11. Echo Therapeutics Receives Frost & Sullivans 2011 Technology Innovation Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Intarcia Therapeutics, Inc. today announced the appointment of ... created role of Vice President, Head of Global Medical ... of leadership experience at leading pharmaceutical, biotechnology, and health ... Most recently Dr. Yee served as VP, Head of ... Officer at AstraZeneca, where he led medical affairs across ...
(Date:2/8/2016)... BASEL , Switzerland and PALO ALTO, Calif. ... leader in biological and chemical manufacturing, and Kodiak Sciences ... for the treatment of retinal disease, announced today agreements ... the agreement, Lonza will manufacture material at multiple sites, ... --> --> Retinal ...
(Date:2/8/2016)... 2016 /PRNewswire/--  Cell Applications, Inc. and Cyfuse ... are now available in North America ... bioprinting approach called the "Kenzan Method." Utilizing Cyfuse ... state-of-the-art robotic system that fabricates 3D tissue from ... bio-printing model that makes scaffold-free tissue available immediately ...
Breaking Medicine Technology:
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Discover the ... visit over 1,400 booths and 700 companies. Attendees also get to see the ... Colorado Garden & Home Show , at the Colorado Convention Center - 700 ...
(Date:2/8/2016)... ... 2016 , ... The Association of Home Care Coding & ... Health and Hospice ICD-10 Transition Workgroup are working closely with the American Hospital ... to address concerns over the use of 'A' as the seventh character indicating ...
(Date:2/8/2016)... Vegas, Nevada (PRWEB) , ... February 08, 2016 ... ... at RowdMap, Inc., will be speaking on how healthcare companies can use newly ... costs, manage the health of a population and intervene and capture the value ...
(Date:2/8/2016)... ... ... The schedule is now online for the largest and most ... being held May 25-29 at the Loews Chicago O’Hare Hotel, continues to give the ... chronic illness in children. , Very recent articles have cited 1 child in 20 ...
(Date:2/7/2016)... Michigan (PRWEB) , ... February 07, 2016 , ... ... organ prolapse with the latest techniques and the most minimally invasive approaches. , ... organ prolapse, particularly after menopause. Other risk factors include surgery to the pelvic ...
Breaking Medicine News(10 mins):